NCT00864604

Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Actavis Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the relative bioavailability of two formulations of nabumetone tablets to establish their average bioequivalence

Detailed description

Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design. Official Title: Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers Further study details as provided by Actavis Elizabeth LLC: Primary Outcome Measures: Rate and Extend of Absorption

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Nabumetone 750 mg tablets, single dose	A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
DRUG	Nabumetone 750 mg tablets, single dose	B: Active comparator Subjects received Teva formulated products under fed conditions

Timeline

• Start date: 2007-04-01
• Primary completion: 2007-05-01
• Completion: 2007-05-01
• First posted: 2009-03-19
• Last updated: 2020-01-07

Locations

1 site across 1 country: United States